Tag: Caberdost 0.5 mg

Introduction Caberdost 0.5 mg contains a preparation of cabergoline, a D₂ receptor agonist of dopamine commonly employed to manage hyperprolactinemia and prolactin-secreting pituitary adenomas (prolactinomas). With compelling evidence supporting its ability to normalize prolactin and reduce tumor size, cabergoline has become the Gold Standard—generally used in place of bromocriptine—within the first-line strategy for both micro- and macroadenomas. This review discusses how Caberdost functions, its clinical efficacy, dosing regimens, safety issues, real-world insights, and patient monitoring suggestions.  How Caberdost 0.5 mg Works Cabergoline is a dopamine agonist—acting like the inhibitory hormone dopamine to suppress prolactin release from pituitary lactotroph cells. Its long half-life (~63–69 hours) supports once- […]